ImaginAb signs new license and supply agreement with Leucid Bio for CD8 ImmunoPET technology

pharmafile | April 12, 2023 | News story | Sales and Marketing  

Biotechnology company ImaginAb has announced that it has signed a new non-exclusive License and Supply Agreement (LSA) with Leucid Bio. ImaginAb focuses on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent as well as radiopharmaceutical therapies (RPT), while Leucid Bio generally focus on new approaches to developing next generation CAR T-cell therapies using its Lateral CAR Platform.

According to the terms of the new agreement, ImaginAb will license and supply clinical doses of the investigational CD8 ImmunoPET tracer to Leucid Bio for use in its basket study for solid tumours, with LEU011 targeting NKG2DL, Autologous CAR T-cells.

Ian Wilson, chief executive officer of ImaginAb, commented: “We are delighted that Leucid Bio will use our investigational CD8 ImmunoPET for the first time in conjunction with CAR T therapies. This agreement with Leucid Bio is an opportunity for ImaginAb to continue expanding our partnerships and showcases the increasing adoption of our CD8 ImmunoPET technology.”

Artin Moussavi, chief business officer at Leucid Bio, added: “This is an exciting partnership for Leucid as this cutting edge technology will provide evidence of the biodistribution of LEU011 CAR T-cells. This will be the first time this technology will be used in a solid tumour CAR T clinical setting allowing Leucid to generate data that demonstrates the tracking of LEU011 to tumour sites in the first phase of the trial. This data would validate, in humans, the significant improvements already demonstrated with LEU011 in preclinical studies.”


Betsy Goodfellow

Related Content

No items found

Latest content